1.            Rouvinski, A. et al. Antibody response in elderly vaccinated four times with an mRNA anti-COVID-19 vaccine. Sci. Rep. 13, (2023).

2.            Günther, G. et al. Relative cost of multidrug-resistant TB medicines in Europe. Int. J. Tuberc. Lung Dis. 27, 341–344 (2023).

3.            Wiessing, L. et al. Impact of COVID-19 & Response Measures on HIV-HCV Prevention Services and Social Determinants in People Who Inject Drugs in 13 Sites with Recent HIV Outbreaks in Europe, North America and Israel. AIDS Behav. 27, 1140–1153 (2023).

4.            Losev, Y. et al. Genomic, phenotypic and demographic characterization of Mycobacterium tuberculosis in Israel in 2021. Front. Cell. Infect. Microbiol. 13, (2023).

5.            Günther, G. et al. Availability and costs of medicines for the treatment of tuberculosis in Europe. Clin. Microbiol. Infect. 29, 77–84 (2023).

6.            Guglielmetti, L. et al. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. Eur. Respir. J. 59, (2022).

7.            Wagner, T. et al. Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010–2018. Viruses 14, (2022).

8.            Chemtob, D. et al. Drop-out of medical follow-up among people living with HIV in Tel-Aviv area. AIDS Care - Psychol. Socio-Medical Asp. AIDS/HIV 34, 621–625 (2022).

9.            Chemtob, D., Weil, C., Attal, J. H., Hawila, E. & Sadeh, E. N. HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis. PLoS One 16, (2021).

10.          Chemtob, D. & Ogum, E. Tuberculosis treatment outcomes of non-citizen migrants: Israel compared to other high-income countries. Isr. J. Health Policy Res. 9, (2020).

11.          Des Jarlais, D. C. et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV 7, e434–e442 (2020).

12.          Chowers, M. et al. Continuum of HIV care of newly diagnosed individuals in Israel, 2011–2015: a population-based cohort study. Int. J. STD AIDS 31, 326–334 (2020).

13.          Ginsberg, G. M. & Chemtob, D. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. BMC Public Health 20, (2020).

14.          Bishara, H. et al. Ongoing tuberculosis transmission among second-generation Ethiopian immigrants in Israel. Epidemiol. Infect. (2020) doi:10.1017/S0950268820001715.

15.          Mårdh, O. et al. HIV among women in the WHO European Region – Epidemiological trends and predictors of late diagnosis, 2009-2018. Eurosurveillance 24, (2019).

16.          Chemtob, D. et al. Ensuring HIV care to undocumented migrants in Israel: a public-private partnership case study. Isr. J. Health Policy Res. 8, (2019).

17.          Hayes, R. et al. Estimating the ‘PrEP Gap’: How implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. Eurosurveillance 24, (2019).

18.          Chemtob, D., Mor, Z., Harel, N. & Averick, N. HIV infection among men who have sex with men in Israel: A 35-year epidemiological and clinical overview, 1981-2015. BMC Public Health 19, (2019).

19.          Ganzel, C., Silverman, B., Chemtob, D., Ben Shoham, A. & Wiener-Well, Y. The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm: a large population-based cohort study. Leuk. Lymphoma 60, 720–725 (2019).

20.          Kiros, Y. K. et al. Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel. HIV Med. 20, 33–37 (2019).

21.          Brown, A. E. et al. HIV in Europe and central Asia: Progress in 2018 towards meeting the UNAIDS 90-90-90 targets. Eurosurveillance 23, (2018).

22.          Bui, L. V, Mor, Z., Chemtob, D., Ha, S. T. & Levine, H. Use of geographically weighted poisson regression to examine the effect of distance on tuberculosis incidence: A case study in Nam Dinh, Vietnam. PLoS One 13, (2018).

23.          Avidor, B. et al. Evaluation of the virtues and pitfalls in an HIV screening algorithm based on two fourth generation assays – A step towards an improved national algorithm. J. Clin. Virol. 106, 18–22 (2018).

24.          Popovici, O. et al. Cross-border outbreak of extensively drug-resistant tuberculosis linked to a university in Romania. Epidemiol. Infect. 146, 824–831 (2018).

25.          Rakovsky, A. et al. Diagnosis of HIV-1 infection: Performance of Xpert Qual and Geenius supplemental assays in fourth generation ELISA-reactive samples. J. Clin. Virol. 101, 7–10 (2018).

26.          Mor, Z., Sheffer, R. & Chemtob, D. Causes of death and mortality trends of all individuals reported with HIV/AIDS in Israel, 1985-2010. J. Public Heal. (United Kingdom) 40, 56–64 (2018).

27.          Mor, Z., Sheffer, R. & Chemtob, D. Mother-to-child HIV transmissions in Israel, 1985-2011. Epidemiol. Infect. 145, 1913–1921 (2017).

28.          Katchman, E. et al. Successful control of a large outbreak of HIV infection associated with injection of cathinone derivatives in Tel Aviv, Israel. Clin. Microbiol. Infect. 23, 336.e5-336.e8 (2017).

29.          Chemtob, D. et al. A national strategic plan for reducing the burden of sexually transmitted infections in Israel by the year 2025. Isr. J. Health Policy Res. 6, (2017).

30.          Freidlin, P. J. et al. Structure and variation of CRISPR and CRISPR-flanking regions in deleted-direct repeat region Mycobacterium tuberculosis complex strains. BMC Genomics 18, (2017).

31.          Chowers, M. et al. Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009–2014. Hum. Vaccines Immunother. 13, 216–219 (2017).

32.          Ginsberg, G. M., Shinar, E., Kopel, E. & Chemtob, D. Should Men who have sex with Men be allowed to donate blood in Israel. Isr. J. Health Policy Res. 5, (2016).

33.          Mor, Z., Lidji, M., Chemtob, D., Cedar, N. & Grotto, I. Erratum: ‘HIV prevalence in the Israeli tuberculosis cohort, 1999-2011’ (BMC Public Health (2014) 14 (1090)). BMC Public Health 16, (2016).

34.          Hofstra, L. M. et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin. Infect. Dis. 62, 655–663 (2016).

35.          Shuldiner, J., Leventhal, A., Chemtob, D. & Mor, Z. Mortality after anti-tuberculosis treatment completion: Results of long-term follow-up. Int. J. Tuberc. Lung Dis. 20, 43–48 (2016).

36.          Chemtob, D. et al. Impact of Male Circumcision among heterosexual HIV cases: Comparisons between three low HIV prevalence countries. Isr. J. Health Policy Res. 4, (2015).

37.          Chemtob, D., Mor, Z. & Grotto, I. Tuberculosis screening programmes for migrants to low-incidence countries-the Israeli experience. Lancet Infect. Dis. 15, 876 (2015).

38.          Lönnroth, K. et al. Towards tuberculosis elimination: An action framework for low-incidence countries. Eur. Respir. J. 45, 928–952 (2015).

39.          Mor, Z. et al. Drug-resistant tuberculosis in Israel: Risk factors and treatment outcomes. Int. J. Tuberc. Lung Dis. 18, 1195–1201 (2014).

40.          Goldblatt, D. et al. Molecular epidemiology and mapping of tuberculosis in Israel: Do migrants transmit the disease to locals? Int. J. Tuberc. Lung Dis. 18, 1085–1091 (2014).

41.          Frentz, D. et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect. Dis. 14, (2014).

42.          Shuldiner, J., Leventhal, A., Chemtob, D. & Mor, Z. Mortality of tuberculosis patients during treatment in israel, 2000-2010. Int. J. Tuberc. Lung Dis. 18, 818-823+ii (2014).

43.          D’Ambrosio, L. et al. Tuberculosis elimination: Theory and practice in Europe. Eur. Respir. J. 43, 1410–1420 (2014).

44.          Mor, Z., Lidji, M., Cedar, N., Grotto, I. & Chemtob, D. Tuberculosis incidence in HIV/AIDS patients in Israel, 1983-2010. PLoS One 8, (2013).

45.          Mor, Z., Weinstein, R., Grotto, I., Levin, Y. & Chemtob, D. Thirty years of HIV in Israel: Current epidemiology and future challenges. BMJ Open 3, (2013).

46.          Frentz, D. et al. Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology 10, (2013).

47.          Theys, K. et al. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology 9, (2012).

48.          Chemtob, D., Zenilman, J. M. & Gandacu, D. What do we need to learn for policy decision-making on sexually transmitted infections prevention and treatment in Israel? Int. J. STD AIDS 23, e11–e15 (2012).

49.          Merrick, J. et al. Human immunodeficiency virus (HIV) and persons with disability/intellectual disability. in AIDS and Tuberculosis: Public Health Aspects 23–30 (Nova Science Publishers, Inc., 2012).

50.          Schenker, I., Chemtob, D., Yamin, N., Shtechman, N. & Rosenberg, H. The National HIV/AIDS hotline in Israel: Data on utilization, quality assurance and content. in AIDS and Tuberculosis: Public Health Aspects 107–115 (Nova Science Publishers, Inc., 2012).

51.          Chemtob, D. et al. Epidemiology of Hepatitis B, Hepatitis C and HIV infections among intravenous drug users in Jerusalem, Israel. in AIDS and Tuberculosis: Public Health Aspects 117–126 (Nova Science Publishers, Inc., 2012).

52.          Chemtob, D. & Merrick, J. Introduction: Preventing and treating tuberculosis and HIV/AIDS. A worldwide public health challenge. AIDS Tuberc. Public Heal. Asp. xvii–xx (2012).

53.          Chemtob, D. & Merrick, J. AIDS and Tuberculosis: Public Health Aspects. AIDS and Tuberculosis: Public Health Aspects (Nova Science Publishers, Inc., 2012).

54.          Chemtob, D. & Rosenberg, E. Healthy Israel 2020: Objectives, targets, and evidence-based strategies to prevent tuberculosis and HIV infection in Israel. in AIDS and Tuberculosis: Public Health Aspects 31–46 (Nova Science Publishers, Inc., 2012).

55.          Gross, S. et al. Human immunodificiency virus (HIV) in a residential care center for persons with intellectual disability in Israel: A needle in a haystack investigation. in AIDS and Tuberculosis: Public Health Aspects 133–141 (Nova Science Publishers, Inc., 2012).

56.          Mor, Z. et al. High-risk behaviour in steady and in casual relationships among men who have sex with men in Israel. Sex. Transm. Infect. 87, 532–537 (2011).

57.          Alvarez, G. G. et al. Pediatric tuberculosis immigration screening in high-immigration, low-incidence countries (International Journal of Tuberculosis and Lung Disease (2010) 14, 12, (1530-1537)). Int. J. Tuberc. Lung Dis. 15, 425 (2011).

58.          Alvarez, G. G. et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect. Dis. 11, (2011).

59.          Alvarez, G. G. et al. Pediatric tuberculosis immigration screening in high-immigration, low-incidence countries. Int. J. Tuberc. Lung Dis. 14, 1530–1537 (2010).

60.          Erkens, C. G. M. et al. Tuberculosis contact investigation in low prevalence countries: A European consensus. Eur. Respir. J. 36, 925–949 (2010).

61.          Chemtob, D. & Levy, A. Rationale and staff evaluation of using a therapeutic milieu for substance users within a tuberculosis ward. Subst. Use Misuse 44, 672–683 (2009).

62.          Attamna, A. et al. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: A nationwide cohort. Thorax 64, 271 (2009).

63.          Bothamley, G. H. et al. Active case finding of tuberculosis in Europe: A Tuberculosis Network European Trials Group (TBNET) survey. Eur. Respir. J. 32, 1023–1030 (2008).

64.          Mor, Z., Davidovich, U., McFarlane, M., Feldshtein, G. & Chemtob, D. Gay men who engage in substance use and sexual risk behaviour: A dual-risk group with unique characteristics. Int. J. STD AIDS 19, 698–703 (2008).

65.          Chemtob, D. et al. ‘Injecting clean or being clean?’ The International and Israeli experiences of Syringe Exchange Programs among injecting drugs users. Harefuah 147, 634–638 (2008).

66.          Chemtob, D. Mortality of hospitalized tuberculosis patients in Israel. Isr. Med. Assoc. J. 10, (2008).

67.          Mor, Z. et al. Tuberculosis behind bars in Israel: Policy making within a dynamic situation. Isr. Med. Assoc. J. 10, 202–206 (2008).

68.          Mor, Z., Chemtob, D., Hildesheimer, G. M. & Leventhal, A. Aids and the right to privacy. Harefuah 146, 200–205 (2007).

69.          Chemtob, D., Sasson, M., Leventhal, A., Stein-Zamir, C. & Maayan, S. Sexually transmitted infections among individuals with and without HIV [1]. Isr. Med. Assoc. J. 8, 892 (2006).

70.          Mor, Z., Chemtob, D., Pessach, N. & Nitzan-Kaluski, D. Human immunodeficiency virus in newborn of infected mothers: Pregnancy, breast feeding and prevention. Harefuah 145, 682–686 (2006).

71.          Chemtob, D. et al. ‘Getting AIDS: Not in my back yard.’ Results from a national knowledge, attitudes and practices survey. Isr. Med. Assoc. J. 8, 610–614 (2006).

72.          Chemtob, D., Weiler-Ravell, D., Leventhal, A. & Bibi, H. Epidemiologic characteristics of pediatric active tuberculosis among immigrants from high to low tuberculosis-endemic countries: The Israeli experience. Isr. Med. Assoc. J. 8, 21–26 (2006).

73.          Chemtob, D. & Srour, S. F. Epidemiology of HIV infection among Israeli Arabs. Public Health 119, 138–143 (2005).

74.          Chemtob, D. & Grossman, Z. Epidemiology of adult and adolescent HIV infection in Israel: A country of immigration. Int. J. STD AIDS 15, 691–696 (2004).

75.          Weiler-Ravell, D., Leventhal, A., Berlowitz, Y., Rishpon, S. & Chemtob, D. Circumstances leading to the formulation and implementation of a new TB control program in Israel: A case study in public health and policy. J. Public Health Policy 25, 23–37 (2004).

76.          Weiler-Ravell, D., Leventhal, A., Coker, R. J. & Chemtob, D. Compulsory detention of recalcitrant tuberculosis patients in the context of a new uberculosis control programme in Israel. Public Health 118, 323–328 (2004).

77.          Chemtob, D., Leventhal, A. & Weiler-Ravell, D. Screening and management of tuberculosis in immigrants: The challenge beyond professional competence. Int. J. Tuberc. Lung Dis. 7, 959–966 (2003).

78.          Chemtob, D., Leventhal, A., Berlowitz, Y. & Weiler-Ravell, D. The new National Tuberculosis Control Programme in Israel, a country of high immigration. Int. J. Tuberc. Lung Dis. 7, 828–836 (2003).

79.          Leventhal, A., Berlowitz, Y. & Chemtob, D. Migrant workers: Evolution of the Israel health system approach to the new social issue. Harefuah 142, 632-635+644 (2003).

80.          Chemtob, D. & Nitzan Kaluski, D. Political commitment and public health prioritization. Isr. Med. Assoc. J. 4, 234 (2002).

81.          Bibi, H. et al. Compliance to treatment of latent tuberculosis infection in a region of Israel. Isr. Med. Assoc. J. 4, 13–16 (2002).

82.          Chemtob, D., Leventhal, A. & Weiler-Ravell, D. Tuberculosis in Israel--main epidemiological aspects. Harefuah 141, 226-232,316 (2002).

83.          Chemtob, D., Leventhal, A., Berlowitz, Y. & Weiler-Ravell, D. The new national program for tuberculosis elimination in Israel. Harefuah 141, 265-271,314 (2002).

84.          Grossman, Z. et al. Erratum: Genotypic variation of HIV-1 reverse transcriptase and protease: Comparative analysis of clade C and clade B (AIDS (2001) 15 (1453-1460)). [1]. AIDS 15, 2209 (2001).

85.          Chemtob, D., Epstein, L., Slater, P. E. & Weiler-Ravell, D. Epidemiological analysis of tuberculosis treatment outcome as a tool for changing TB control policy in Israel. Isr. Med. Assoc. J. 3, 479–483 (2001).

86.          Grossman, Z. et al. Genotypic variation of HIV-1 reverse transcriptase and protease: Comparative analysis of clade C and clade B. AIDS 15, 1453–1460 (2001).

87.          Ravins, M., Bercovier, H., Chemtob, D., Fishman, Y. & Rahav, G. Molecular epidemiology of Mycobacterium tuberculosis infection in Israel. J. Clin. Microbiol. 39, 1175–1177 (2001).

88.          Chemtob, D., Weiler-Ravell, D. & Ben-Dov, I. Incorrect estimation of TB drug resistance in Israel, probably due to recruitment and collection biases [2] (multiple letters). Int. J. Tuberc. Lung Dis. 4, 990–992 (2000).

89.          Srour-Fihmi, S., Weiler-Ravell, D., Kitzes, R. & Chemtob, D. Routine two-step skin testing for tuberculosis in the staff of a geriatric hospital in Israel: Booster and conversion rates. J. Hosp. Infect. 46, 141–146 (2000).

90.          Chemtov, D. & Rosen, H. Epidemiological and cultural factors in the case of hepatitis B virus infection among Ethiopian adolescents in Israel. Int. J. Adolesc. Med. Health 6, 95–112 (1993).

91.          Shtarkshall, R., Soskolne, V., Chemtov, D. & Rosen, H. A culturally specific educational program to reduce the risk of HIV and HBV transmission among Ethiopian immigrants to Israel. II: Evaluating the effect of the training program on veteran immigrant trainees. Isr. J. Med. Sci. 29, 48–54 (1993).

92.          Chemtov, D., Rosen, H., Shtarkshall, R. & Soskolne, V. A culturally specific educational program to reduce the risk of HIV and HBV transmission among Ethiopian immigrants to Israel: A preliminary report on training veteran immigrants as health educators. Isr. J. Med. Sci. 29, 437–442 (1993).

93.          Senba, M., Chemtob, D., Slater, P. E., Fassberg, J. & Larouze, B. Prevention of chronic carriage of hepatitis B virus infection in Ethiopian immigrants [2]. Isr. J. Med. Sci. 28, 308–309 (1992).

94.          Chemtob, D. et al. Prevention strategy of hepatitis B virus infection among the Ethiopian Community in Israel. Isr. J. Med. Sci. 27, 273–277 (1991).

95.          Chemtob, D., Kalka, I. & Fassberg, Y. Research note: Blood drawing and hepatitis B ‐‐ the case of Ethiopian Jews in Israel. Sociol. Health Illn. 12, 216–226 (1990).